231 results
6-K
EX-5.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, fully paid and non-assessable. Except as expressly set forth herein, we have not undertaken any independent investigation to determine the existence
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
bid price per ADS so reported, or (d) in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good … independent registered accounting firm is set forth in the Prospectus. To the knowledge and belief of the Company, such accounting firm (i
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation … of the Warrant ADSs to the Company’s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
, the commercialization of our therapeutic candidates independently. In this regard, we are currently executing on an independent commercialization plan for APHEXDA in stem … Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given
20-F/A
2023 FY
EX-15.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration
20-F/A
hdyexyzlui9c8b0w2
26 Mar 24
Annual report (foreign) (amended)
4:57pm
S-8
p7z556
29 Dec 23
Registration of securities for employees
4:20pm
S-8
EX-23.2
a8gm525fmbpc8m
29 Dec 23
Registration of securities for employees
4:20pm
F-3
EX-23.1
vcjh k7qcr
29 Dec 23
Shelf registration (foreign)
4:15pm
F-3
pldnei8zdm03bd0z6mx
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
w3bnt39bx dxoy0c6t
12 Dec 23
Current report (foreign)
7:07am
6-K
EX-99
cxpll2oua8 133
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
5h9brb946 34ww
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
h6a9zd1mbt876
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
yec4rx2m2twq1tfgmzm0
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
dgn oet5o5x0
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
6a6gn2kpzheqg99
30 Aug 23
Current report (foreign)
6:45am
6-K
bx5dov 0o8
8 Aug 23
Current report (foreign)
5:25pm